Chronic Obstructive Pulmonary Disease and Mild Cognitive Impairment: A Survey on Disease Management and Intervention Strategies

www.surveyx.cn

Abstract

Chronic Obstructive Pulmonary Disease (COPD) and Mild Cognitive Impairment (MCI) are significant public health concerns due to their prevalence and impact on patient outcomes. This survey paper explores the intersection of these conditions, emphasizing the role of disease management and intervention strategies in enhancing cognitive function and overall health. Pulmonary rehabilitation emerges as a pivotal intervention, offering cognitive benefits that extend beyond respiratory health. The paper systematically reviews intervention strategies, including pharmacological, non-pharmacological, and technological innovations, highlighting their potential to improve patient outcomes. Technological advancements, such as machine learning frameworks, enhance diagnostic accuracy and facilitate personalized interventions. The survey also addresses the challenges in diagnosing and monitoring COPD and MCI, underscoring the need for innovative, non-invasive diagnostic tools. Integrative approaches, particularly personalized medicine, are emphasized for their potential to tailor treatments to individual patient profiles, improving efficacy and outcomes. The paper concludes by identifying future research directions, focusing on the integration of advanced technologies and methodologies to overcome current limitations and enhance the management of COPD and MCI. These findings underscore the transformative impact of comprehensive disease management strategies in improving health outcomes for individuals with COPD and MCI.

1 Introduction

1.1 Significance of COPD and MCI

Chronic Obstructive Pulmonary Disease (COPD) and Mild Cognitive Impairment (MCI) are significant public health concerns due to their prevalence and detrimental effects on patient outcomes. COPD, characterized by persistent respiratory symptoms and airflow limitation, is a leading cause of morbidity and mortality globally, impacting millions and placing immense strain on healthcare systems [1, 2]. Despite advancements in management, COPD remains a major cause of death, highlighting the urgent need for ongoing research and intervention [3]. While primarily linked to tobacco smoking, COPD can also affect non-smokers, necessitating comprehensive diagnostic strategies [4]. Moreover, the heightened vulnerability of COPD patients to severe infections, including COVID-19, underscores the challenges in managing this condition [5].

MCI, defined by cognitive decline that exceeds typical age-related changes, is a precursor to Alzheimer's disease [6]. The rising prevalence of MCI is anticipated due to aging populations and growing awareness [7]. Early detection is complex, as current diagnostic methods often overlook the subtle cognitive deficits associated with MCI [8]. This complexity necessitates the development of sensitive diagnostic tools [9]. Both COPD and MCI require urgent attention and innovative strategies to mitigate their impact on individuals and healthcare systems [10].



Figure 1: chapter structure

1.2 Importance of Disease Management

Effective disease management is crucial for enhancing patient outcomes in chronic conditions like COPD and MCI. The intricate nature of these diseases, particularly the subtle cognitive decline in MCI, complicates their management [11]. For COPD, conventional diagnostic methods such as spirometry may inadequately capture the disease's full spectrum, emphasizing the need for comprehensive management strategies that integrate innovative diagnostic tools. Automated, non-invasive systems for classifying lung sounds are essential for improving diagnostic accuracy and efficiency [12].

The socio-economic burden associated with COPD and MCI is significant, driven by high healthcare resource utilization and the necessity for ongoing patient management [2]. Management strategies must prioritize reducing exacerbation rates in COPD and enhancing early detection and intervention in MCI. The incorporation of adaptive learning frameworks, similar to those utilized in dynamic environments, can improve the management of these conditions [10].

Moreover, structured care plans, including adherence to scheduled appointments, have proven cost-effective for managing chronic diseases [13]. The development of a search engine prototype to assist healthcare professionals in accessing relevant COPD information highlights the importance of efficient resource utilization and information dissemination [14]. Identifying patients at risk of severe symptoms and mortality remains a priority, facilitating targeted management and early intervention [15]. Effective disease management is vital for mitigating the impacts of COPD and MCI, ensuring optimal patient care and resource allocation.

AI-generated, for reference only.

1.3 Structure of the Survey

This survey is systematically structured to provide a comprehensive overview of COPD and MCI, with a focus on disease management and intervention strategies. The introduction establishes the significance of COPD and MCI as critical public health issues, highlighting their prevalence and the need for effective management approaches. The background section offers detailed definitions and insights into COPD and MCI, exploring their impacts on health and the relationship between respiratory efficiency and cognitive function.

The survey subsequently examines intervention strategies specific to COPD, including pulmonary rehabilitation, pharmacological and non-pharmacological interventions, and technological innovations in management. It then shifts focus to MCI, affecting 10-15

A key section highlights integrative approaches to disease management, emphasizing the potential of personalized medicine and multidisciplinary strategies to concurrently address COPD and MCI. The role of pulmonary rehabilitation in enhancing cognitive function is investigated, presenting evidence of cognitive improvements and frameworks for implementation.

The survey concludes by addressing challenges and future directions, including diagnostic and monitoring difficulties, areas requiring further research, and limitations in current methodologies. The final section synthesizes the key points discussed, reinforcing the importance of comprehensive disease management and intervention strategies in enhancing health outcomes for individuals with COPD and MCI.The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Definitions and Prevalence of COPD and MCI

Chronic Obstructive Pulmonary Disease (COPD) is a progressive inflammatory lung disease characterized by persistent respiratory symptoms and irreversible airflow limitation, affecting millions globally and ranking as a leading cause of morbidity and mortality. While smoking is a primary risk factor, non-smokers are also susceptible, necessitating comprehensive diagnostic approaches [10]. Traditional diagnostics like spirometry face practical and cost-related challenges, limiting accessibility [16]. COPD's significant healthcare burden requires extensive resources, particularly when relying on administrative data [17]. Moreover, COPD exacerbates comorbid conditions, including COVID-19, increasing severity and mortality risks.

Mild Cognitive Impairment (MCI) involves cognitive decline, such as memory and thinking skills, exceeding age-related expectations but not significantly impairing daily life [6]. It acts as a transitional phase to more severe dementias like Alzheimer's Disease (AD), with prevalence rising among older adults, affecting approximately 55 million globally [18]. Current diagnostics, often reliant on linguistic and cognitive assessments, struggle with accuracy and accessibility, missing subtle declines [11]. The urgent need for reliable, cost-effective, and non-invasive biomarkers is crucial to prevent MCI progression [18]. Both COPD and MCI pose significant health challenges, demanding innovative management strategies [10].

2.2 Impact on Health and Quality of Life

COPD and MCI substantially impact health and quality of life, challenging healthcare systems. COPD is linked to increased healthcare utilization, frequent hospitalizations, and reduced quality of life [1]. Despite declining exacerbation rates, their unpredictability strains hospitals [19]. COPD's heterogeneity complicates classification and management [20]. Current diagnostics like spirometry lack specificity, and respiratory symptom assessments are often subjective, failing to consider environmental factors. Automated tools are needed to improve diagnostic accuracy, particularly for emphysema detection [21].

COPD patients face a five-fold increased risk of severe COVID-19 infection compared to the general population [5], highlighting the need for comprehensive management strategies that prioritize overall health [17].

MCI presents challenges in thorough neuropsychological assessments and lacks cost-effective, non-invasive early detection methods [22]. As a transitional phase to severe dementias, MCI significantly impacts older adults [23]. Subtle cognitive changes complicate early interventions [24]. Amnestic MCI progresses to Alzheimer's at a higher rate than non-amnestic MCI [6]. Reliable biomarkers are essential to prevent MCI progression [18].

Both conditions impose significant burdens, necessitating comprehensive management strategies addressing their multifaceted nature. Effective disease prediction is challenging due to complex datasets with noise and insufficient information [25]. The synthesis of heterogeneous and incomplete data complicates intervention strategy development [26]. Addressing COPD and MCI's health impacts requires innovative management strategies, ensuring healthcare professionals efficiently access relevant literature [14].

2.3 Relationship Between Respiratory Efficiency and Cognitive Function

The relationship between respiratory efficiency and cognitive function is pivotal, especially in COPD and MCI. COPD's persistent airflow limitation and respiratory symptoms contribute to cognitive impairments due to reduced oxygenation affecting brain function [1]. This relationship highlights the need for comprehensive approaches addressing both respiratory and cognitive health.

Genetic and environmental factors influence COPD development, impacting lung function throughout life [3]. Addressing respiratory efficiency is crucial to mitigating cognitive decline. Advanced technologies like wearable spirometry offer promising enhancements in respiratory assessment, indirectly supporting cognitive health through continuous monitoring [16].

Integrating speech analysis techniques into cognitive assessments, as demonstrated by the CogniVoice framework, offers new insights into the respiratory-cognitive function relationship [27]. This approach utilizes multimodal data for deeper cognitive impairment understanding, providing diagnostic and therapeutic benefits.

Multi-task learning systems using demographic data to assess COPD risk exemplify innovative diagnostic tools informing cognitive health interventions [12]. However, integrating heterogeneous data sources remains challenging, requiring effective tools for actionable insights [28].

Comorbidities like COVID-19 in COPD patients complicate management, affecting respiratory and cognitive outcomes [15]. This complexity necessitates comprehensive strategies addressing these conditions' multifaceted nature.

3 Intervention Strategies for COPD

Category	Feature	Method
Pulmonary Rehabilitation and Its Challenges	Rehabilitation Approaches	SBGM[29], CTA[30], MBIDDD[31], BECC[26]
Pharmacological and Non-Pharmacological Interventions	Personalized Approaches	SE-CRS[32], DS[33], PHKG[28], CTHMM[1]
	Data Segmentation Strategies	WDBQM[17]
	Technology Enhancement	VDSNet[25]
Technological Innovations in COPD Management	Real-Time Monitoring	PB[34]
	Advanced Model Structures	VRN[35]
	Learning Strategies	MTL-LSDC[12], SA[16]

Table 1: This table provides a comprehensive overview of various intervention strategies and methodologies employed in the management of Chronic Obstructive Pulmonary Disease (COPD). It categorizes the approaches into pulmonary rehabilitation challenges, pharmacological and non-pharmacological interventions, and technological innovations, highlighting specific methods and features associated with each category. The table serves as a resource for understanding the multi-faceted strategies aimed at improving COPD patient outcomes.

Managing Chronic Obstructive Pulmonary Disease (COPD) involves implementing diverse intervention strategies to enhance patient outcomes and quality of life. This section explores key components of these strategies, beginning with pulmonary rehabilitation (PR), which aims to alleviate symptoms, improve physical function, and tackle the multifaceted challenges patients face in accessing and completing rehabilitation programs. Table 2 presents a comprehensive overview of the various intervention strategies employed in the management of COPD, detailing their primary focus, the challenges they address, and the innovative approaches utilized in each domain. Additionally, Table 1 presents a detailed classification of COPD intervention strategies, emphasizing the integration of rehabilitation, pharmacological, and technological advancements in disease management.

?? illustrates the intervention strategies for COPD, categorizing them into pulmonary rehabilitation challenges and innovations, pharmacological and non-pharmacological interventions, and technological advancements. This figure highlights not only the challenges and innovative approaches in pulmonary rehabilitation but also the integration of pharmacological and non-pharmacological treatments, as well as the impact of technological innovations in improving COPD management. By visualizing these components, we gain a clearer understanding of the complex landscape of interventions available for COPD patients.

3.1 Pulmonary Rehabilitation and Its Challenges

Pulmonary rehabilitation is a cornerstone in COPD management, focusing on enhancing physical function, reducing symptoms, and improving quality of life [36]. Despite its effectiveness, PR faces implementation challenges, especially in outpatient settings where infrastructure and referral processes are inadequate [36]. Barriers such as limited awareness of PR benefits, high travel costs, and logistical issues contribute to low uptake and completion rates.

A significant challenge in effective PR delivery is managing COPD exacerbations at home, complicated by vague diagnostic criteria and symptom variability, often leading to delayed responses [30]. The use of traditional inhalers, which may not provide immediate relief, exacerbates patient distress during exacerbations [31]. Furthermore, many COPD patients are nonsmokers or exhibit normal spirometry results, complicating diagnosis and treatment, underscoring the need for comprehensive, individualized PR strategies [3].

Innovative approaches like home-based programs, such as PulmoBell, address geographical and logistical barriers by offering flexible, patient-tailored rehabilitation options [34]. These programs incorporate education, physical activity, psychological support, and airway clearance techniques, customized according to the severity of the patient's condition [37]. Smoking cessation remains crucial in PR, significantly impacting COPD management [38].

Advanced methodologies, including adversarial learning-based models, can enhance the objectivity and efficiency of analyses, informing PR strategies through insights derived from complex data [29]. Clustering techniques can segment COPD patient data, feeding into multi-class queuing models to optimize resource allocation [17]. Additionally, innovative diagnostic tools utilizing negative binomial frameworks improve parameter estimation, providing clearer insights into PR outcomes [26].

Addressing the challenges associated with pulmonary rehabilitation is essential for improving accessibility, engagement, and effectiveness, ultimately leading to better health outcomes for COPD patients. Overcoming barriers related to patient knowledge, service inefficiencies, and organizational constraints, while exploring innovative delivery methods such as online rehabilitation programs, is crucial. These programs have shown comparable benefits to traditional face-to-face approaches [39, 37, 40, 41, 42]. Enhancing knowledge dissemination, optimizing referral processes, and leveraging technological advancements are vital for delivering effective rehabilitation solutions.

3.2 Pharmacological and Non-Pharmacological Interventions

Pharmacological interventions in COPD primarily involve bronchodilators and corticosteroids, which are essential for symptom relief, reducing exacerbations, and improving lung function [1]. Advanced computational techniques, such as machine learning algorithms, enhance the prediction of COPD exacerbations, enabling timely pharmacological adjustments based on individual patient data. Personalized medicine approaches, supported by mechanistic models, allow for treatment customization to align with specific patient responses and disease phenotypes [32].

Non-pharmacological interventions include lifestyle modifications, pulmonary rehabilitation (PR), and technological innovations, which complement pharmacological treatments to improve patient outcomes [1]. PR integrates exercise therapy, nutritional counseling, and psychosocial support, enhancing physical and psychological well-being [36]. Innovative delivery methods, such as online PR programs, improve accessibility and adherence, offering digital platforms for exercise and education that replicate traditional models. The effectiveness of PR in enhancing respiratory function and quality of life has been demonstrated across various settings, including those affected by COVID-19 [37].

To illustrate these concepts, Figure 2 presents a hierarchical structure of interventions for managing COPD, categorizing them into pharmacological, non-pharmacological, and technological advancements. Each category includes specific approaches, highlighting the integration of personalized medicine, pulmonary rehabilitation, and innovative technologies to enhance COPD management.

Technological advancements, like the Personal Health Knowledge Graph (PHKG) framework, integrate clinical data and guidelines to generate insights for chronic disease management, supporting non-pharmacological strategies [28]. Deep learning frameworks, such as DeepSpiro, provide innovative diagnostic tools by analyzing spirogram time series data to detect and predict COPD risk [33]. Additionally, the application of 3D deep learning approaches, including modified VoxResNet architectures, enhances the classification of COPD and emphysema through volume-wise annotations [35]. VDSNet, integrating VGG, data augmentation, and spatial transformer networks with CNN, improves lung disease detection accuracy, exemplifying the potential of technological innovations in informing non-pharmacological interventions [25].

Integrating pharmacological and non-pharmacological interventions, supported by technological advancements and personalized approaches, is essential for comprehensive COPD management. These strategies aim to alleviate symptoms, prevent exacerbations, and enhance quality of life by addressing the disease's multifaceted nature. The application of clustering techniques to segment COPD patient data, along with multi-class queuing models, optimizes resource allocation within healthcare settings, supporting effective disease management [17].



Figure 2: This figure illustrates the hierarchical structure of interventions for managing COPD, categorizing them into pharmacological, non-pharmacological, and technological advancements. Each category includes specific approaches, highlighting the integration of personalized medicine, pulmonary rehabilitation, and innovative technologies to enhance COPD management.

3.3 Technological Innovations in COPD Management

Technological innovations have significantly advanced COPD management, improving diagnostic accuracy, monitoring capabilities, and treatment outcomes. Notably, integrating multiple deep learning architectures within a multi-task learning framework enhances classification accuracy and reduces training time compared to traditional single-task approaches [12]. This innovation facilitates efficient and accurate analysis of lung sounds, contributing to better disease management.

Active learning strategies in wearable spirometry technologies represent another significant development, allowing effective data acquisition with fewer samples than traditional methods [16]. This approach enhances the accessibility and efficiency of respiratory monitoring, providing continuous and reliable data to inform treatment decisions.

In imaging, advanced methodologies, such as deep learning architectures like VoxResNet, have improved the classification of COPD and emphysema from CT images [35]. These technologies enable precise identification of pulmonary abnormalities, supporting tailored treatment strategies.

Sensor-based assistive devices like PulmoBell enhance home-based rehabilitation experiences by providing real-time feedback and support, addressing accessibility challenges and promoting patient engagement in rehabilitation programs [34]. Telemedicine innovations, including pulmonary tele-rehabilitation (PTR), leverage digital platforms to deliver remote services, improving patient adherence and outcomes [41].

Advancements in technology, including machine learning algorithms for patient triage, innovative rehabilitation strategies, and the development of wearable spirometry devices, highlight the transformation in COPD management. These innovations enhance early detection and response to exacerbations, improve accessibility and engagement in rehabilitation programs, and ultimately lead to better patient outcomes and more personalized care [2, 16, 43, 30, 41]. By enhancing diagnostic precision, facilitating continuous monitoring, and enabling personalized treatment strategies, these advancements offer new avenues for improving patient care and outcomes in COPD management.

Feature	Pulmonary Rehabilitation and Its Challenges	Pharmacological and Non-Pharmacological Interventions	Technological Innovations in COPD Management
Primary Focus	Enhance Physical Function	Symptom Relief	Diagnostic Accuracy
Challenges Addressed	Low Uptake Rates	Exacerbation Prediction	Monitoring Capabilities
Innovative Approaches	Home-based Programs	Personalized Medicine	Multi-task Learning

Table 2: This table provides a comparative analysis of intervention strategies for managing Chronic Obstructive Pulmonary Disease (COPD), highlighting the primary focus, challenges addressed, and innovative approaches across three domains: pulmonary rehabilitation, pharmacological and non-pharmacological interventions, and technological innovations. It underscores the multifaceted nature of COPD management and the integration of diverse strategies to enhance patient outcomes.

4 Intervention Strategies for MCI

4.1 Cognitive Training and Reminiscence Therapy

Cognitive training (CT) and reminiscence therapy (RT) are pivotal in managing Mild Cognitive Impairment (MCI), focusing on enhancing cognitive functions and delaying dementia progression. CT involves structured exercises targeting memory, attention, and problem-solving, with significant improvements noted in cognitive performance and quality of life for older adults [44]. Technological advancements have introduced innovative CT methods, such as augmented reality (AR)-based cognitive training, which uses interactive games and motion sensor technology like Kinect to create engaging environments that stimulate cognitive processes [45]. Intelligent assistive systems integrating AR and serious games further assess and enhance cognitive abilities, representing a promising direction for CT interventions [46].

RT, conversely, focuses on discussing past experiences to stimulate cognitive processes and improve emotional well-being. Traditional RT often requires in-person therapist guidance, limiting accessibility. To address this, automated support systems have been developed. These coimagination systems enable therapeutic interactions via voice commands, promoting cognitive engagement through meaningful dialogues that stimulate episodic memory, attention, and planning [27, 47, 48, 49].

Moreover, advanced diagnostic techniques, such as short-term ECG analysis, enhance cognitive training by providing insights into cognitive health, enabling targeted interventions [8]. Machine learning algorithms analyzing verbal utterances as behavioral biomarkers for dementia demonstrate the intersection of cognitive training and innovative diagnostics, paving new avenues for early intervention and cognitive decline management [50].

As illustrated in Figure 3, the hierarchical structure of cognitive training and reminiscence therapy interventions for managing MCI highlights key components such as cognitive training techniques, reminiscence therapy methods, and innovative diagnostic approaches. This visual representation underscores the interconnectedness of these strategies in fostering cognitive health and enhancing therapeutic outcomes.

4.2 Pharmacological and Lifestyle Interventions

The management of Mild Cognitive Impairment (MCI) increasingly emphasizes pharmacological and lifestyle interventions aimed at mitigating cognitive decline and enhancing quality of life. Despite extensive research, pharmacological treatments have not consistently shown efficacy, largely due to inconsistent diagnostic criteria and assessment practices [6]. Consequently, lifestyle interventions, particularly exercise, have gained prominence for their ability to enhance cognitive function and delay dementia onset [51].

Recent advancements in predictive modeling have improved understanding of MCI progression, informing both pharmacological and lifestyle strategies. The use of frameworks like the multiview



Figure 3: This figure illustrates the hierarchical structure of cognitive training and reminiscence therapy interventions for managing Mild Cognitive Impairment (MCI), highlighting key components such as cognitive training techniques, reminiscence therapy methods, and innovative diagnostic approaches.

imputation cross-attention network offers promising opportunities for refining intervention strategies [7]. Additionally, deep learning approaches analyzing PET images provide valuable insights into cognitive decline likelihood, supporting targeted intervention development [52].

Socially assistive robots (SARs) in cognitive therapies offer a novel approach, with studies comparing their effectiveness to traditional human-led interventions [44]. These robots can provide consistent and personalized cognitive support, complementing pharmacological treatments.

Technological advancements have also bolstered lifestyle interventions. AR technologies facilitate the creation of engaging, culturally relevant training programs that integrate physical and cognitive activities, enhancing lifestyle intervention effectiveness [45]. The CogniVoice framework exemplifies the integration of multimodal data for predicting MCI and Mini-Mental State Examination (MMSE) scores, providing a comprehensive approach to cognitive assessment and intervention [27].

Furthermore, AI-based dialogue systems like Elisabot utilize personal photos to create tailored reminiscence therapy sessions, simulating a therapist and offering a personalized approach to cognitive engagement [49]. These technological innovations, alongside traditional lifestyle modifications, create a robust framework for managing MCI, underscoring the necessity for ongoing research and innovation in this field.

4.3 Innovative Diagnostic and Monitoring Methods

Innovative diagnostic and monitoring methods for Mild Cognitive Impairment (MCI) increasingly leverage advanced technologies for enhanced early detection and intervention strategies. The MU-COPART program, an augmented reality initiative, improves executive functions through home-based physical activities tailored for older adults with MCI, demonstrating the potential of immersive technologies in cognitive assessment and rehabilitation [45]. Combining eye-tracking systems with heart rate variability monitoring offers a cost-effective dual approach for evaluating cognitive function and stress, serving as a comprehensive tool for early MCI detection [18].

Natural Language Processing (NLP) techniques have demonstrated effectiveness in differentiating between MCI and normal cognitive conditions. A novel InfoLoss function has achieved an average AUC of 84.75

Elisabot exemplifies the application of automated systems in therapeutic contexts, utilizing a Visual Question Generator and chatbot model to facilitate engaging reminiscence therapy sessions for dementia patients, thereby enhancing cognitive engagement through personalized interactions [49]. These advancements illustrate the convergence of technology and cognitive science, paving the way for personalized intervention strategies tailored to individual cognitive profiles.

5 Integrative Approaches in Disease Management

5.1 Integrative Approaches and Personalized Medicine

Integrative approaches, particularly personalized medicine, are pivotal in managing Chronic Obstructive Pulmonary Disease (COPD) and Mild Cognitive Impairment (MCI) by tailoring healthcare to individual patient characteristics, thereby improving treatment efficacy [2]. COPD, being multifactorial, necessitates customized treatment strategies [3]. The Continuous-Time Hidden Markov Model (CTHMM) exemplifies this by modeling disease progression based on healthcare utilization, enabling precise interventions [1]. Adaptive learning frameworks further refine management strategies by aligning interventions with updated patient data [10].

The integration of diverse data sources through systems like the Personal Health Knowledge Graph (PHKG) provides personalized alerts and insights, offering a comprehensive view of patient health [28]. This holistic approach facilitates tailored interventions by incorporating clinical, demographic, and lifestyle data. Innovative segmentation and analysis techniques utilizing underexplored administrative data are crucial in advancing personalized healthcare, especially in understanding comorbidities and symptoms affecting outcomes, such as those related to COVID-19 [17, 15]. In MCI, the need for standardized assessment tools is underscored by its diverse phenomenological and neurobiological aspects [6]. Personalized medicine addresses these complexities by developing targeted interventions based on individual cognitive profiles and disease trajectories.

The application of integrative and personalized medicine in managing COPD and MCI shows significant promise. Employing innovative strategies and technologies allows healthcare providers to deliver personalized treatments, enhancing accessibility and engagement in rehabilitation programs for chronic conditions like COPD. Advanced search tools and patient-centric designs improve referrals and participation in rehabilitation, leading to more successful health interventions [14, 53, 41].

5.2 Multidisciplinary and Personalized Approaches

The integration of multidisciplinary and personalized approaches is essential in managing the complex needs of patients with COPD and MCI. Multidisciplinary care involves collaboration among healthcare professionals—physicians, nurses, respiratory therapists, and cognitive specialists—to provide comprehensive, coordinated care tailored to individual needs [40]. This approach enhances care quality and facilitates the identification and management of barriers to effective intervention, particularly in pulmonary rehabilitation programs.

As illustrated in Figure 4, the integration of these approaches emphasizes key components such as comprehensive care, patient-centered strategies, and innovative techniques that enhance treatment outcomes. Personalized strategies complement multidisciplinary care by focusing on patient-centered approaches that consider the unique characteristics and preferences of each individual. Advanced methodologies, such as frameworks for simultaneous categorization of multiple continuous variables in regression contexts, enable precise treatment outcomes [54]. This allows for nuanced patient data analysis, facilitating customized interventions based on a comprehensive understanding of disease progression and patient response.

The synergy of multidisciplinary and personalized approaches enhances care delivery for COPD and MCI patients, addressing both physiological and cognitive dimensions. Innovative rehabilitation strategies, predictive modeling, and machine learning techniques improve patient engagement, optimize treatment outcomes, and effectively manage the complexities associated with these conditions [14, 43, 30, 55, 41]. This integrated strategy not only improves patient outcomes but also optimizes resource allocation within healthcare systems, ultimately enhancing the overall quality of life for affected individuals.

6 Role of Pulmonary Rehabilitation in Cognitive Function

6.1 Cognitive Benefits of Pulmonary Rehabilitation

Pulmonary rehabilitation (PR) plays a crucial role in enhancing cognitive function for patients with Chronic Obstructive Pulmonary Disease (COPD), complementing its established benefits in physical health and quality of life, especially post-acute exacerbations (AECOPD) [42]. PR, encompassing



Figure 4: This figure illustrates the integration of multidisciplinary and personalized approaches in managing COPD and MCI, highlighting key components such as comprehensive care, patient-centered strategies, and innovative techniques that enhance treatment outcomes.

exercise, education, and behavioral interventions, significantly improves cognitive outcomes by addressing cognitive impairments common in COPD patients.

As illustrated in Figure 5, the cognitive benefits of pulmonary rehabilitation (PR) are evident across various contexts. This figure highlights PR's role in enhancing cognitive function in COPD patients, improving adherence through supervised pulmonary tele-rehabilitation (PTR), and aiding cognitive recovery in post-COVID-19 scenarios.

Supervised pulmonary tele-rehabilitation (PTR) demonstrates that while it may not surpass traditional PR in improving physical metrics like walking distance, it achieves higher completion rates, indicating better adherence and cognitive engagement [56]. This suggests that a structured approach can enhance cognitive outcomes by maintaining patient motivation.

PR's efficacy extends to post-COVID-19 recovery, where it effectively mitigates cognitive and physical impairments, underscoring its adaptability in addressing cognitive decline from severe respiratory conditions [57]. Systems like the PulmoBell home-based platform exemplify how PR can foster cognitive benefits by offering real-time, context-sensitive feedback that promotes safe physical activity and cognitive engagement [34]. Such feedback mechanisms stimulate cognitive processes, contributing to improved cognitive outcomes.



Figure 5: This figure illustrates the cognitive benefits of pulmonary rehabilitation (PR) across different contexts, highlighting its role in enhancing cognitive function in COPD patients, improving adherence through supervised pulmonary tele-rehabilitation (PTR), and aiding cognitive recovery in post-COVID-19 scenarios.

6.2 Frameworks for Pulmonary Rehabilitation

Effective pulmonary rehabilitation (PR) frameworks are essential for customizing interventions to meet the specific needs of COPD patients. PR is categorized into inpatient and outpatient settings, emphasizing adaptable frameworks for both acute and chronic care [42].

Inpatient PR focuses on intensive rehabilitation during acute exacerbations to stabilize patients and prepare them for discharge, integrating exercise, education, and psychosocial support to enhance respiratory function and overall health. Outpatient PR frameworks emphasize sustained rehabilitation to support long-term health maintenance and prevent disease progression. The PulmoBell initiative exemplifies home-based rehabilitation that overcomes participation barriers, while research on stratified patient appointment scheduling highlights the importance of accommodating patient time preferences to improve adherence and health management in community-based chronic disease programs [34, 13].

Technological advancements, such as the VDSNet framework, enhance PR effectiveness by improving disease classification accuracy and addressing image orientation issues [25]. This hybrid approach enables precise patient assessments and personalized rehabilitation plans, enhancing adherence and outcomes.

PR frameworks must remain dynamic and responsive to the evolving needs of COPD patients. By categorizing PR into inpatient and outpatient settings and incorporating technological innovations, these frameworks develop comprehensive strategies to address the unique challenges faced by individuals with COPD, thereby improving both respiratory and cognitive health outcomes. This approach aims to enhance access and engagement in PR, reduce attrition rates, and ensure better patient adherence and quality of life through innovative delivery methods, including online programs and home-based assistive technologies [39, 37, 34, 40, 41].

7 Challenges and Future Directions

7.1 Challenges in Diagnosis and Monitoring

Diagnosing and monitoring Chronic Obstructive Pulmonary Disease (COPD) and Mild Cognitive Impairment (MCI) present considerable challenges that hinder effective management. COPD's diagnostic complexity arises from its heterogeneous manifestations, complicating the development of precise diagnostic tools and classifier training [58]. Logistical difficulties in obtaining consistent spirometry measurements across diverse settings further impede accurate diagnosis [16]. The absence of passive monitoring methods integrating respiratory event tracking with environmental factors exacerbates misdiagnosis and delays early intervention [59]. Additionally, reliance on administrative data, which may not capture all relevant patient interactions or health outcomes, limits current monitoring approaches [17].

In MCI, early detection is challenging due to traditional neuropsychological methods' inability to adequately capture subtle linguistic impairments [9]. High costs and invasiveness of current diagnostic methods limit accessibility [18]. The lack of uncertainty assessment in predictive methods complicates clinical decision-making, as clinicians may be hesitant to trust prognostic information without understanding its reliability [60]. Moreover, the extensive training time required for deep learning methods on large datasets may restrict their clinical application [25].

Innovative, non-invasive diagnostic tools that provide accurate and culturally unbiased assessments are essential. Coherent modeling approaches integrating diverse data formats, as demonstrated in meta-analyses, show promise for improving parameter estimates and enhancing the validity of clinical studies' conclusions [26]. Addressing these diagnostic and monitoring challenges is crucial for advancing COPD and MCI management, ultimately improving patient outcomes and healthcare delivery.

7.2 Future Research Directions

Future research in managing COPD and MCI should focus on integrating advanced technologies and methodologies to enhance patient outcomes. As illustrated in Figure 6, key areas of focus include COPD management, MCI detection, and the integration of technology. In COPD, incorporating additional covariates like age and comorbidities is crucial for improving model predictive power, facilitating personalized management strategies [1]. Exploring variable labeling costs and developing neural networks utilizing audio signals for predicting lung health indices are promising areas for further exploration, potentially leading to more accurate and accessible diagnostic tools [16].

For MCI, developing standardized assessment tools and identifying novel biomarkers for early detection could significantly enhance diagnostic accuracy and intervention strategies. Future research should focus on understanding the impact of demographic factors such as age, gender, and education level on diagnostic frameworks, particularly regarding Alzheimer's disease detection. Enhancing the calibration of eye-tracking systems and expanding training datasets will improve validation in clinical environments. Integrating diverse data sources, including facial videos and audio recordings from clinical interviews, aims to create reliable cognitive assessments, ultimately leading to better diagnostic tools and interventions for cognitive decline [61, 62, 23, 18, 63].

Moreover, integrating additional disease ontologies and improving clinical system user interfaces can enhance access to critical information, aiding clinician decision-making. Investigating interactions between comorbidities and COVID-19 outcomes in diverse populations presents opportunities for developing targeted therapeutic interventions. Future research should also enhance chatbots' contextual understanding by integrating advanced natural language processing techniques and multimodal features, improving their effectiveness in delivering reminiscence therapy for dementia patients. This includes exploring AI-driven dialogue systems that utilize personal memories and linguistic cues to provide tailored support, making therapeutic interventions more engaging for individuals with mild cognitive impairment and other dementia stages [50, 62, 49, 11].

These research directions emphasize the importance of continued innovation and technology integration in treatment plans to enhance COPD and MCI management. By focusing on innovative multimodal approaches, such as AI-driven tools for early diagnosis and automated therapy, future studies can develop personalized and accessible interventions for cognitive decline and chronic conditions like COPD, ultimately improving early detection and treatment engagement for better health outcomes.



Figure 6: This figure illustrates the future research directions in managing COPD and MCI, highlighting key areas such as COPD management, MCI detection, and technological integration. The focus is on incorporating additional covariates, developing neural networks, and exploring variable labeling costs for COPD, while MCI research emphasizes standardized tools, novel biomarkers, and demographic factors. Technological integration includes enhancing disease ontologies, chatbots, and AI-driven dialogue systems.

7.3 Limitations in Current Research Methodologies

Current research methodologies in managing COPD and MCI face limitations that hinder effective intervention strategies. A significant challenge is the performance degradation of federated learning models with non-IID (non-independent and identically distributed) data, leading to weight divergence and affecting classification accuracy [55]. This complicates the application of machine learning techniques in clinical settings, where data heterogeneity is prevalent.

In MCI research, studies often overlook the potential effects of plasticity in network synchronization, which could significantly influence cognitive outcomes [64]. This oversight limits understanding of neural adaptability and its impact on cognitive function, necessitating further exploration of dynamic network properties.

Additionally, reliance on retrospective data analysis in large language models poses limitations, as these benchmarks might not generalize across diverse medical conditions or clinical environments

[65]. This restricts the applicability of findings and underscores the need for prospective studies that validate model performance in real-world scenarios.

The assumptions of independence between rate and overdispersion parameters in Bayesian methods also present challenges, potentially affecting parameter estimate accuracy [26]. Moreover, the computational costs associated with these methods complicate their widespread adoption in clinical research.

To address these limitations, future research should focus on developing robust methodologies that account for data heterogeneity and network plasticity. Enhancing machine learning model generalizability through diverse and prospective data collection can improve applicability in clinical practice. Optimizing computational efficiency in Bayesian methods can significantly enhance the accuracy and scalability of analyses related to COPD and MCI. This improvement is crucial for developing effective decision support tools, such as machine learning algorithms predicting exacerbations in COPD patients and analyzing complex datasets with diverse patient populations. Employing advanced techniques like Wasserstein distance for parameter recovery and integrating multiple data sources can help researchers better understand these populations' health needs, leading to more informed interventions and improved patient outcomes [66, 67, 68, 30, 17].

8 Conclusion

The exploration of Chronic Obstructive Pulmonary Disease (COPD) and Mild Cognitive Impairment (MCI) underscores the critical demand for strategic management and intervention to enhance patient health outcomes. The interconnectedness of respiratory and cognitive functions necessitates an integrated treatment approach. Pulmonary rehabilitation emerges as a pivotal intervention, offering dual benefits by improving both cognitive and respiratory health, thus serving as a cornerstone in holistic disease management frameworks.

Technological advancements, such as the CPML framework, demonstrate significant potential in forecasting COPD exacerbations, thereby augmenting clinical decision-making and patient management. Similarly, the deployment of intelligent assistive systems for MCI patients has shown substantial enhancements in performing daily activities, reflecting a strong alignment with traditional cognitive assessments. These technological innovations highlight the transformative capacity of modern tools in providing tailored and effective interventions.

The survey advocates for comprehensive approaches that incorporate personalized medicine and multidisciplinary care to effectively manage the complexities of COPD and MCI. By leveraging advanced methodologies and emerging technologies, healthcare providers can deliver personalized treatments that significantly improve patient outcomes and life quality. The identified challenges and limitations in current research methodologies point to the necessity for ongoing innovation and the creation of robust, scalable solutions to meet the dynamic needs of individuals affected by these conditions.

AI-generated, for reference only.

References

[1] Aman Verma, Guido Powell, Yu Luo, David Stephens, and David L. Buckeridge. Modeling disease progression in longitudinal ehr data using continuous-time hidden markov models, 2018.

[2] Andreas Triantafyllopoulos, Markus Fendler, Anton Batliner, Maurice Gerczuk, Shahin Amiriparian, Thomas M. Berghaus, and Björn W. Schuller. Distinguishing between pre- and post-treatment in the speech of patients with chronic obstructive pulmonary disease, 2022.

[3] Alvar Agustí and James C Hogg. Update on the pathogenesis of chronic obstructive pulmonary disease. *New England Journal of Medicine*, 381(13):1248–1256, 2019.

[4] Katherine E Lowe, Elizabeth A Regan, Antonio Anzueto, Erin Austin, John HM Austin, Terri H Beaty, Panayiotis V Benos, Christopher J Benway, Surya P Bhatt, Eugene R Bleecker, et al. Copdgene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease. *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation*, 6(5):384, 2019.

[5] Giuseppe Lippi and Brandon Michael Henry. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (covid-19). *Respiratory medicine*, 167:105941, 2020.

[6] Nicole D Anderson. State of the science on mild cognitive impairment (mci). *CNS spectrums*, 24(1):78–87, 2019.

[7] Tao Wang, Xiumei Chen, Xiaoling Zhang, Shuoling Zhou, Qianjin Feng, and Meiyan Huang. Multi-view imputation and cross-attention network based on incomplete longitudinal and multimodal data for conversion prediction of mild cognitive impairment, 2023.

[8] Anjo Xavier, Sneha Noble, Justin Joseph, and Thomas Gregor Issac. Heart rate and its variability from short-term ecg recordings as biomarkers for detecting mild cognitive impairment in indian population, 2024.

[9] Sylvester Olubolu Orimaye, Kah Yee Tai, Jojo Sze-Meng Wong, and Chee Piau Wong. Learning linguistic biomarkers for predicting mild cognitive impairment using compound skip-grams, 2015.

[10] Piero Giacomelli, Giulia Munaro, and Roberto Rosso. Using soft computer techniques on smart devices for monitoring chronic diseases: the chronious case, 2011.

[11] Ali Pourramezan Fard, Mohammad H. Mahoor, Muath Alsuhaibani, and Hiroko H. Dodgec. Linguistic-based mild cognitive impairment detection using informative loss, 2024.

[12] Suma K V au2, Deepali Koppad, Preethi Kumar, Neha A Kantikar, and Surabhi Ramesh. Multi-task learning for lung sound lung disease classification, 2024.

[13] Martin Savelsbergh and Karen Smilowitz. Stratified patient appointment scheduling for community-based chronic disease management programs, 2015.

[14] Stephan Kiefer, Jochen Rauch, Riccardo Albertoni, Marco Attene, Franca Giannini, Simone Marini, Luc Schneider, Carlos Mesquita, Xin Xing, and Michael Lawo. The chronious ontology-driven search tool: Enabling access to focused and up-to-date healthcare literature, 2011.

[15] Sakifa Aktar, Ashis Talukder, Md. Martuza Ahamad, A. H. M. Kamal, Jahidur Rahman Khan, Md. Protikuzzaman, Nasif Hossain, Julian M. W. Quinn, Mathew A. Summers, Teng Liaw, Valsamma Eapen, and Mohammad Ali Moni. Machine learning and meta-analysis approach to identify patient comorbidities and symptoms that increased risk of mortality in covid-19, 2020.

[16] Ankita Kumari Jain, Nitish Sharma, Madhav Kanda, and Nipun Batra. Spiroactive: Active learning for efficient data acquisition for spirometry, 2024.

[17] Henry Wilde, Vincent Knight, Jonathan Gillard, and Kendal Smith. Segmentation analysis and the recovery of queuing parameters via the wasserstein distance: a study of administrative data for patients with chronic obstructive pulmonary disease, 2020.

[18] Danilo Greco, Francesco Masulli, Stefano Rovetta, Alberto Cabri, and Davide Daffonchio. A cost-effective eye-tracker for early detection of mild cognitive impairment, 2024.

[19] Stefan Andreas, Christian Röver, Judith Heinz, Sebastian Straube, Henrik Watz, and Tim Friede. Decline of copd exacerbations in clinical trials over two decades – a systematic review and meta-regression, 2019.

[20] Silvia D. Almeida, Carsten T. Lüth, Tobias Norajitra, Tassilo Wald, Marco Nolden, Paul F. Jaeger, Claus P. Heussel, Jürgen Biederer, Oliver Weinheimer, and Klaus Maier-Hein. coopd: Reformulating copd classification on chest ct scans as anomaly detection using contrastive representations, 2023.

[21] Isabel Pino Peña, Veronika Cheplygina, Sofia Paschaloudi, Morten Vuust, Jesper Carl, Ulla Møller Weinreich, Lasse Riis Østergaard, and Marleen de Bruijne. Automatic emphysema detection using weakly labeled hrct lung images, 2018.

[22] Muath Alsuhaibani, Hiroko H. Dodge, and Mohammad H. Mahoor. Detection of mild cognitive impairment using facial features in video conversations, 2023.

[23] Jian Sun, Hiroko H. Dodge, and Mohammad H. Mahoor. Mc-vivit: Multi-branch classifier-vivit to detect mild cognitive impairment in older adults using facial videos, 2024.

[24] Eufemia Lella and Gennaro Vessio. Ensembling complex network 'perspectives' for mild cognitive impairment detection with artificial neural networks, 2021.

[25] Subrato Bharati, Prajoy Podder, and M. Rubaiyat Hossain Mondal. Hybrid deep learning for detecting lung diseases from x-ray images, 2020.

[26] Christian Röver, Stefan Andreas, and Tim Friede. Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data, 2014.

[27] Jiali Cheng, Mohamed Elgaar, Nidhi Vakil, and Hadi Amiri. Cognivoice: Multimodal and multilingual fusion networks for mild cognitive impairment assessment from spontaneous speech, 2024.

[28] Daniel Bloor, Nnamdi Ugwuoke, David Taylor, Keir Lewis, Luis Mur, and Chuan Lu. Towards a personal health knowledge graph framework for patient monitoring, 2023.

[29] Heng Kong and Shuqiang Wang. Adversarial learning based structural brain-network generative model for analyzing mild cognitive impairment, 2022.

[30] Sumanth Swaminathan, Klajdi Qirko, Ted Smith, Ethan Corcoran, Nicholas G Wysham, Gaurav Bazaz, George Kappel, and Anthony N Gerber. A machine learning approach to triaging patients with chronic obstructive pulmonary disease. *PloS one*, 12(11):e0188532, 2017.

[31] Evan Carroll, Nicholas Recchione, Jean Paul Rojas Henao, Vincent G. Capone, and Sleiman R. Ghorayeb Ph. D. Microfluidic bioelectrical impedance drug delivery device for patients with acute exacerbations of chronic obstructive pulmonary disease, 2024.

[32] Varghese Kurian, Navid Ghadipasha, Michelle Gee, Anais Chalant, Teresa Hamill, Alphonse Okossi, Lucy Chen, Bin Yu, Babatunde A. Ogunnaike, and Antony N. Beris. A systems engineering approach to modeling and analysis of chronic obstructive pulmonary disease (copd), 2022.

[33] Shuhao Mei, Xin Li, Yuxi Zhou, Jiahao Xu, Yong Zhang, Yuxuan Wan, Shan Cao, Qinghao Zhao, Shijia Geng, Junqing Xie, Shengyong Chen, and Shenda Hong. Deep learning for detecting and early predicting chronic obstructive pulmonary disease from spirogram time series, 2024.

[34] Yuanxiang Ma, Andreas Polydorides, Jitesh Joshi, and Youngjun Cho. Pulmobell: Home-based pulmonary rehabilitation assistive technology for people with copd, 2023.

[35] Jalil Ahmed, Sulaiman Vesal, Felix Durlak, Rainer Kaergel, Nishant Ravikumar, Martine Remy-Jardin, and Andreas Maier. Copd classification in ct images using a 3d convolutional neural network, 2020.

[36] Rainer Gloeckl, Tessa Schneeberger, Inga Jarosch, and Klaus Kenn. Pulmonary rehabilitation and exercise training in chronic obstructive pulmonary disease. *Deutsches Ärzteblatt International*, 115(8):117, 2018.

[37] Tina J Wang, Brian Chau, Mickey Lui, Giang-Tuyet Lam, Nancy Lin, and Sarah Humbert. Physical medicine and rehabilitation and pulmonary rehabilitation for covid-19. *American journal of physical medicine & rehabilitation*, 99(9):769–774, 2020.

[38] Ian Shrier and Etsuji Suzuki. The primary importance of the research question: Implications for understanding natural versus controlled direct effects and the 'cross-world independence assumption', 2021.

[39] Simon Bourne, Ruth DeVos, Malcolm North, Anoop Chauhan, Ben Green, Thomas Brown, Victoria Cornelius, and Tom Wilkinson. Online versus face-to-face pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: randomised controlled trial. *BMJ open*, 7(7):e014580, 2017.

[40] Ramin Sami, Kobra Salehi, Marzieh Hashemi, and Vajihe Atashi. Exploring the barriers to pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a qualitative study. *BMC Health Services Research*, 21:1–10, 2021.

[41] Renae J McNamara, Marita Dale, and Zoe J McKeough. Innovative strategies to improve the reach and engagement in pulmonary rehabilitation. *Journal of thoracic disease*, 11(Suppl 17):S2192, 2019.

[42] Sarah E Jones, Ruth E Barker, Claire M Nolan, Suhani Patel, Matthew Maddocks, and William DC Man. Pulmonary rehabilitation in patients with an acute exacerbation of chronic obstructive pulmonary disease. *Journal of thoracic disease*, 10(Suppl 12):S1390, 2018.

[43] Negar Orangi-Fard. Prediction of copd using machine learning, clinical summary notes, and vital signs, 2024.

[44] King Tai Henry Au-Yeung, William Wai Lam Chan, Kwan Yin Brian Chan, Hongjie Jiang, and Junpei Zhong. A pilot study on the comparison of prefrontal cortex activities of robotic therapies on elderly with mild cognitive impairment, 2024.

[45] Sirinun Chaipunko, Watthanaree Ammawat, Keerathi Oanmun, Wanvipha Hongnaphadol, Supatida Sorasak, and Pattrawadee Makmee. A pretest-posttest pilot study for augmented reality-based physical-cognitive training in community-dwelling older adults at risk of mild cognitive impairment, 2024.

[46] Fatemeh Ghorbani, Mahsa Farshi Taghavi, and Mehdi Delrobaei. Towards an intelligent assistive system based on augmented reality and serious games, 2023.

[47] Nana Lin, Youxiang Zhu, Xiaohui Liang, John A. Batsis, and Caroline Summerour. Analyzing multimodal features of spontaneous voice assistant commands for mild cognitive impairment detection, 2024.

[48] John Noel Victorino, Naoto Fukunaga, and Tomohiro Shibata. Design and development of an automated coimagination support system, 2020.

[49] Mariona Caros, Maite Garolera, Petia Radeva, and Xavier Giro i Nieto. Automatic reminiscence therapy for dementia, 2021.

[50] Swati Padhee, Anurag Illendula, Megan Sadler, Valerie L. Shalin, Tanvi Banerjee, Krishnaprasad Thirunarayan, and William L. Romine. Predicting early indicators of cognitive decline from verbal utterances, 2021.

[51] Ronald C Petersen, Oscar Lopez, Melissa J Armstrong, Thomas SD Getchius, Mary Ganguli, David Gloss, Gary S Gronseth, Daniel Marson, Tamara Pringsheim, Gregory S Day, et al. Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. *Neurology*, 90(3):126, 2018.

[52] Hongyoon Choi and Kyong Hwan Jin. Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging, 2017.

[53] Piero Giacomelli, Giulia Munaro, and Roberto Rosso. Can an ad-hoc ontology beat a medical search engine? the chronious search engine case, 2012.

[54] Irantzu Barrio, Javier Roca-Pardiñas, Cristobal Esteban, and Maria Durban. Proposal of a general framework to categorize continuous predictor variables, 2024.

[55] Yiqing Shen, Baiyun Liu, Ruize Yu, Yudong Wang, Shaokang Wang, Jiangfen Wu, and Weidao Chen. Federated learning for chronic obstructive pulmonary disease classification with partial personalized attention mechanism, 2022.

[56] Henrik Hansen, Theresa Bieler, Nina Beyer, Thomas Kallemose, Jon Torgny Wilcke, Lisbeth Marie Østergaard, Helle Frost Andeassen, Gerd Martinez, Marie Lavesen, Anne Frølich, et al. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe copd: a randomised multicentre trial. *Thorax*, 75(5):413–421, 2020.

[57] Elisabetta Zampogna, Mara Paneroni, Stefano Belli, Maria Aliani, Alessandra Gandolfo, Dina Visca, Maria Teresa Bellanti, Nicolino Ambrosino, and Michele Vitacca. Pulmonary rehabilitation in patients recovering from covid-19. *Respiration*, 100(5):416–422, 2021.

[58] Veronika Cheplygina, Lauge Sørensen, David M. J. Tax, Jesper Holst Pedersen, Marco Loog, and Marleen de Bruijne. Classification of copd with multiple instance learning, 2017.

[59] Rohan Tan Bhowmik. A multi-modal respiratory disease exacerbation prediction technique based on a spatio-temporal machine learning architecture, 2021.

[60] Telma Pereira, Sandra Cardoso, Dina Silva, Manuela Guerreiro, Alexandre de Mendonça, and Sara C. Madeira. Ensemble learning with conformal predictors: Targeting credible predictions of conversion from mild cognitive impairment to alzheimer's disease, 2018.

[61] Chuang Li, Rubing Lin, Yantong Liu, and Yichen Wei. Evaluating cognitive and neuropsychological assessments – a comprehensive review, 2024.

[62] David Ortiz-Perez, Jose Garcia-Rodriguez, and David Tomás. Cognitive insights across languages: Enhancing multimodal interview analysis, 2024.

[63] Chaitra Hegde, Yashar Kiarashi, Allan I Levey, Amy D Rodriguez, Hyeokhyen Kwon, and Gari D Clifford. Feasibility of assessing cognitive impairment via distributed camera network and privacy-preserving edge computing, 2024.

[64] Adrián Navas, David Papo, Stefano Boccaletti, F. del Pozo, Ricardo Bajo, Fernando Maestú, Pedro Gil, Irene Sendiña-Nadal, and Javier M. Buldú. Functional hubs in mild cognitive impairment, 2013.

[65] Xiaodan Zhang, Sandeep Vemulapalli, Nabasmita Talukdar, Sumyeong Ahn, Jiankun Wang, Han Meng, Sardar Mehtab Bin Murtaza, Aakash Ajay Dave, Dmitry Leshchiner, Dimitri F. Joseph, Martin Witteveen-Lane, Dave Chesla, Jiayu Zhou, and Bin Chen. Large language models in medical term classification and unexpected misalignment between response and reasoning, 2023.

[66] Zijian Bian, Jean-Paul Charbonnier, Jiren Liu, Dazhe Zhao, David A Lynch, and Bram van Ginneken. Small airway segmentation in thoracic computed tomography scans: A machine learning approach. *Physics in Medicine & Biology*, 63(15):155024, 2018.

[67] Sara Graziadio and Kevin J. Wilson. Uncertainty representation for early phase clinical test evaluations: a case study, 2020.

[68] J. Butts, C. Wendt, R. Bowler, C. P. Hersh, Q. Long, L. Eberly, and S. E. Safo. Accounting for data heterogeneity in integrative analysis and prediction methods: An application to chronic obstructive pulmonary disease, 2023.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.